- Fourth quarter EXPAREL net product sales of $143.9 million in 2023, compared with $138.0 million in 2022. Fourth quarter net product sales were comprised of average daily volume growth of 4 percent. Pacira reports average daily growth rates for EXPAREL to account for differences in the number of selling days per reporting period. There were 61 selling days in each of the fourth quarters of 2023 and 2022.
- Fourth quarter ZILRETTA net product sales of $28.7 million in 2023, compared with $28.0 million in 2022.
- Fourth quarter iovera° net product sales of $6.0 million in 2023, compared with $4.6 million in 2022.
- Other revenue, including sales of bupivacaine liposome injectable suspension and royalties, was $2.6 million in the fourth quarter of 2023, compared with $1.4 million in the fourth quarter of 2022.
2023 Full-Year Preliminary Unaudited Revenue Highlights
- Full-year EXPAREL net product sales of $538.1 million in 2023, compared with $536.9 million in 2022. Full-year net product sales were comprised of average daily volume growth of 5 percent, which was offset by a lower net selling price primarily due to the implementation of 340B Drug Pricing in October 2022 and other contracted relationships. There were 250 selling days in 2023 and 252 selling days in 2022.
- Full-year ZILRETTA net product sales of $111.1 million in 2023, compared with $105.5 million in 2022.
- Full-year iovera° net product sales of $19.7 million in 2023, compared with $15.3 million in 2022.
- Other revenue, including sales of bupivacaine liposome injectable suspension and royalties, was $6.1 million in 2023, compared with $9.1 million in 2022.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.